ArticleThe international journal of cardiovascular imaging2025
Recovery of right ventricular function in patients with transthyretin cardiac amyloidosis after one-year tafamidis administration.
Article in The international journal of cardiovascular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinical Applications of Right Ventricular Strain by Two-Dimensional Speckle-Tracking Echocardiography.Echocardiography (Mount Kisco, N.Y.) · 2026Review
- Differential Effects of Tafamidis on Cardiac Remodelling in Transthyretin Amyloid Cardiomyopathy: Evidence From Contemporary Imaging Data.European journal of clinical investigation · 2026Review
- Echocardiographic assessment of recovery of right ventricular function in patients with transthyretin cardiac amyloidosis after one-year tafamidis administration.The international journal of cardiovascular imaging · 2025Article
- Monitoring ATTR cardiomyopathy - addressing an unmet need by multimodality imaging.The international journal of cardiovascular imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Baseline cardiac functions are known to be potent predictors of cardiovascular events in the natural history of transthyretin amyloid cardiomyopathy (ATTR-CM). However, previous studies have not shown functional and morphological changes in the heart during tafamidis administration. This study aimed to evaluate the effect of tafamidis on cardiac function by measuring right ventricular strain in patients with ATTR-CM. We performed a retrospective analysis of serial transthoracic echocardiography examinations (at baseline and one year after tafamidis introduction) using a vendor-independent speckle-tracking analyzer in patients with ATTR-CM. The entire cohort (n = 33; 30 men; mean age, 81 ± 5 years) was divided into two subgroups: the tafamidis treatment (n = 18) and the control (n = 15). After one-year tafamidis administration (oral tafamidis meglumine, 80 mg once daily), the average value of the right ventricular (RV) free wall longitudinal strain (RVFWLS) significantly improved (-17.8 ± 7.9% vs. -24.5 ± 9.1%, p = 0.001), with a significant decrease in the frequency of positive RVFWLS test result (≥-22.0%) in the treatment subgroup (72% vs. 44%, p = 0.033). Moreover, tafamidis administration had large impact on RVFWLS improvement (p = 0.007, odds ratio: 22.0, 95% confidence interval: 2.344-206.480). A significant recovery of RV function was measured using RVFWLS. This may be one of the pathophysiological mechanisms underlying the favorable effects of tafamidis.
Indexed as
Identifiers
39607611What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.